(PharmaNewsWire.Com, February 21, 2019 ) The latest study by Fact.MR expects the global market for pharyngitis to experience sluggish growth. Towards 2026 end, the global market for pharyngitis is projected to bring in US$ 1,679.0 million revenue. Pharyngitis is the most common manifestation of infection. Antibiotics are given in case of a sore throat, however, they provide very modest benefit. It is still unclear which antibiotic is the best for the treatment of a sore throat. Hence, various research and trials are being conducted to find most effective antibiotic.
Pharyngitis commonly known as a sore throat is caused by viral or bacterial infection. The most common bacteria infecting throat is Group A streptococcus. Various clinical trials are being carried on to find the best formulation effective in treating sore throat. There is also a focus on patients receiving medication as per the clinical needs and also meet their individual requirement. The healthcare industry across the globe is also emphasizing on appropriate diagnosis, drug selection, dosage, drug delivery route, duration of administration, proper follow-up, and correct information on possible side-effects.
The report also profiles companies that are expected to remain active in the expansion of global pharyngitis market through 2026, which include Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, BioStar Pharmaceuticals, Inc., and Zambon Group SpA.
Beta Lactams to Emerge as the Most-Preferred Drug Class
Compared to the various drug class, beta lactams is likely to emerge as one of the most preferred drug class between 2017 and 2026. Beta lactams is projected to bring in nearly US$ 500 million revenue by 2026 end. Beta-lactams include cephalosporins and penicillins. These drugs are active against many harmful organisms. Moreover, the recent development of broad-spectrum beta-lactams antibiotics active against gram-negative organisms has increased their use.
Retail Pharmacies and Drug Stores to Emerge as the Biggest Distribution Channel
Retail pharmacies and drug stores are likely to gain maximum revenue share. By 2026 end, retail pharmacies and drug stores are projected to bring in nearly US$ 700 million revenue. A sore throat is very common, pharmacists can assess specific symptoms as described by patients and based on it can suggest Over the Counter (OTC) drug that available at retail pharmacies and drug stores. One of the most commonly used OTC products for treating sore throat is lozenges. Moreover, pharmaceutical companies are also introducing new products that can offer rapid relief in pain.
Oral Drug Delivery to Gain Maximum Traction between 2017 and 2026
Oral drug delivery is likely to emerge as the most-preferred drug administration route. Oral drug delivery is projected to create an incremental opportunity of over US$ 300 million between 2017 and 2026. Owing to the cost-effectiveness, convenience and high patient compliance, oral drug delivery is witnessing significant growth. However, many drugs are poorly bioavailable when administered. Hence, lipid-based drug delivery system is one of the emerging trends addressing bioavailability challenges. Moreover, oral drug delivery is the least invasive method as compared to other routes. Targeted drug delivery is also an emerging trend, in which the drug is active only in the targeted area.
Table of Contents Covered in the report are:
1. Global Economic Outlook
2. Global Pharyngitis Market - Executive Summary
3. Global Pharyngitis Market Overview 3.1. Introduction 3.1.1. Global Pharyngitis Market Taxonomy 3.1.2. Global Pharyngitis Market Definition 3.2. Global Pharyngitis Market Size (US$ Mn) and Forecast, 2012-2026 3.2.1. Global Pharyngitis Market Y-o-Y Growth 3.3. Global Pharyngitis Market Dynamics 3.4. Supply Chain 3.5. Cost Structure 3.6. Pricing Analysis 3.7. Drug Pipeline Assessment 3.8. Product Life Cycle 3.9. PEST Analysis
4. Global Pharyngitis Market Analysis and Forecast 2012-2026 4.1. Global Pharyngitis Market Size and Forecast By Drug Class, 2012-2026 4.1.1. Beta Lactams Market Size and Forecast, 2012-2026 4.1.1.1. Revenue (US$ Mn) Comparison, By Region 4.1.1.2. Market Share Comparison, By Region 4.1.1.3. Y-o-Y growth Comparison, By Region 4.1.2. Macrolides Market Size and Forecast, 2012-2026 4.1.2.1. Revenue (US$ Mn) Comparison, By Region 4.1.2.2. Market Share Comparison, By Region 4.1.2.3. Y-o-Y growth Comparison, By Region 4.1.3. Cephalosporins Market Size and Forecast, 2012-2026 4.1.3.1. Revenue (US$ Mn) Comparison, By Region 4.1.3.2. Market Share Comparison, By Region 4.1.3.3. Y-o-Y growth Comparison, By Region 4.1.4. Fluoroquinolones Market Size and Forecast, 2012-2026 4.1.4.1. Revenue (US$ Mn) Comparison, By Region 4.1.4.2. Market Share Comparison, By Region 4.1.4.3. Y-o-Y growth Comparison, By Region 4.1.5. Tetracycline Market Size and Forecast, 2012-2026 4.1.5.1. Revenue (US$ Mn) Comparison, By Region 4.1.5.2. Market Share Comparison, By Region 4.1.5.3. Y-o-Y growth Comparison, By Region 4.1.6. Other Products Market Size and Forecast, 2012-2026 4.1.6.1. Revenue (US$ Mn) Comparison, By Region 4.1.6.2. Market Share Comparison, By Region 4.1.6.3. Y-o-Y growth Comparison, By Region 4.2. Global Pharyngitis Market Size and Forecast By Distribution Channel, 2012-2026 4.2.1. Hospital Pharmacies Market Size and Forecast, 2012-2026 4.2.1.1. Revenue (US$ Mn) Comparison, By Region 4.2.1.2. Market Share Comparison, By Region 4.2.1.3. Y-o-Y growth Comparison, By Region 4.2.2. Retail Pharmacies and Drug Stores Market Size and Forecast, 2012-2026 4.2.2.1. Revenue (US$ Mn) Comparison, By Region 4.2.2.2. Market Share Comparison, By Region 4.2.2.3. Y-o-Y growth Comparison, By Region 4.2.3. Online Pharmacies Market Size and Forecast, 2012-2026 4.2.3.1. Revenue (US$ Mn) Comparison, By Region 4.2.3.2. Market Share Comparison, By Region 4.2.3.3. Y-o-Y growth Comparison, By Region 4.3. Global Pharyngitis Market Size and Forecast By Mode of Delivery, 2012-2026 4.3.1. Oral Market Size and Forecast, 2012-2026 4.3.1.1. Revenue (US$ Mn) Comparison, By Region 4.3.1.2. Market Share Comparison, By Region 4.3.1.3. Y-o-Y growth Comparison, By Region 4.3.2. Intravenous Market Size and Forecast, 2012-2026 4.3.2.1. Revenue (US$ Mn) Comparison, By Region 4.3.2.2. Market Share Comparison, By Region 4.3.2.3. Y-o-Y growth Comparison, By Region 4.3.3. Intramuscular Market Size and Forecast, 2012-2026 4.3.3.1. Revenue (US$ Mn) Comparison, By Region 4.3.3.2. Market Share Comparison, By Region 4.3.3.3. Y-o-Y growth Comparison, By Region 4.3.4. Other Mode of Delivery Market Size and Forecast, 2012-2026 4.3.4.1. Revenue (US$ Mn) Comparison, By Region 4.3.4.2. Market Share Comparison, By Region 4.3.4.3. Y-o-Y growth Comparison, By Region
5. North America Pharyngitis Market Size and Forecast, 2012-2026 5.1. North America Outlook 5.2. North America Parent Market Outlook 5.3. North America Target Market Outlook 5.4. Revenue (US$ Mn) Comparison, By Country 5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026 5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026 5.5. Revenue (US$ Mn) Comparison, By Drug Class 5.6. Revenue (US$ Mn) Comparison, By Distribution Channel 5.7. Revenue (US$ Mn) Comparison, By Mode of Delivery
And Continue...
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us Rohit Bhisey Fact.MR 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Email: sales@factmr.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
